Option chain shows key data for IO Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for IO Biotech.

IO Biotech (NASDAQ:IOBT) Stock, Option Chain

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGFY

EFSH

GLMD

HCTI

IOBT

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

WINT

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

ADAG

ATPC

DRMA

EGIO

ENTO

ITOS

LDTC

NCNA

PPBT

PTIX

SQFT

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Crude-oil-4-logo

Earnings

Equities

Eurozone

Commodities

Intraday Update

CNFR

RXRX

SGRP

SIFY

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher

IO Biotech Inc

WIIM

SPRC

SciSparc shares are trading higher after the company announced it received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group.

Biotech

General

CASI

CASI Pharmaceuticals Announces FDA Clinical Hold On CID-103 For Kidney Transplant AMR; IND Application For Phase 1-2 Study In Chronic Immune Thrombocytopenia Remains Open With Accrual Expected To Begin Q1 2025; FDA To Provide Written Response Before Deadline

EVER

EverQuote shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy.

Legal

NTIP

Network-1 Initiates Patent Litigation Against Citadel Securities And Jump Trading For Patents-in-Suit, Which Are Part Of The HFT Patent Portfolio Acquire By HFT Solutions In 2022

Macro Economic Events

Econ #s

Economics

USA Jobless Claims 4-Week Avg. 226.50K; 225.50K Prior

USA Continuing Jobless Claims 1,910K Vs 1,880K Est.; 1,864K Prior

USA Initial Jobless Claims 219K Vs 223K Est.; 220K Prior

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

KULR

KULR Technology Launches Bitcoin Treasury With $21M Purchase Of 217.18 BTC At An Average Price Of $96,556.53, Allocating Up To 90% Of Surplus Cash To Bitcoin Investments; Selects Coinbase Prime For Custody, USDC, And Self-Custodial Wallet Services To Support Its Bitcoin Treasury Strategy

Commercial Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) will release earnings results for the first quarter before the <a href="https://www.benzinga.com/quote/CMC/earnings">opening bell on Monday, Jan. 6, 2025.</a>
Analysts expect the Irving, Texas-based company to report quarterly earnings at 82 cents per share, down from $1.63 per share in the year-ago period. Commercial Metals is expected to report quarterly revenue of $1.88 billion, compared to $2 billion a year ago, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 12, UBS analyst Curt Woodworth downgraded Commercial Metals from Buy to Sell and lowered the price target from $62 to $56.
With the recent buzz around Commercial Metals, some investors may be eyeing potential gains from the company's dividends too. As of now, Commercial Metals offers an annual dividend yield of 1.43%, which is a quarterly dividend amount of 18 cents per share (72 cents a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $420,817 or around 8,333 shares. For a more modest $100 per month or $1,200 per year, you would need $84,184 or around 1,667 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.72 in this case). So, $6,000 / $0.72 = 8,333 ($500 per month), and $1,200 / $0.72 = 1,667 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CMC Price Action: Shares of Commercial Metals gained 1.5% to close at $50.50 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo by BildWerk on Shutterstock

Long Ideas

How To Earn $500 A Month From Commercial Metals Stock Ahead Of Q1 Earnings

Concerns are rising over the safety of smartwatch bands after a new study identified the presence of hazardous chemicals in these popular accessories.
What Happened: A recent study published in the journal Environmental Science &amp; Technology Letters has discovered that smart watch bands may contain harmful substances. These bands, often made from synthetic rubber known as fluoroelastomers, can include perfluorohexanoic acid (PFHxA), a type of &#8220;forever chemical,&#8221; Salon <a href="https://www.salon.com/2024/12/24/forever-chemicals-could-be-entering-your-body-from-smart-watch-bands-study-finds/">reported</a> on Thursday,
PFHxA is part of a group of industrial compounds called&nbsp;per and polyfluoroalkyl substances (PFAS),&nbsp;which are resistant to degradation. These chemicals have been associated with serious health issues, including cancer and infertility. Despite the risks, PFAS are commonly found in various consumer products such as non-stick cookware and water-resistant fabrics.
The study, led by&nbsp;Graham F. Peaslee&nbsp;from&nbsp;the University of Notre Dame,&nbsp;analyzed 22 watch bands from different brands and price ranges. Surprisingly, PFHxA was the most frequently detected compound. Peaslee noted that the public might not&nbsp;recognize fluoroelastomers as a type&nbsp;of PFAS, leading to unintentional exposure.
See Also:&nbsp;<a href="https://www.benzinga.com/24/12/42666163/iphone-17-pro-could-retain-iconic-triangular-camera-design-despite-rumors-of-a-radical-horizontal-layout?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">iPhone 17 Pro To Retain Iconic &#8216;Triangular&#8217; Camera Layout Despite Rumors Of Radical Horizontal Layout</a>
Although the study did not involve human testing, the researchers warned that high PFAS levels in these bands could lead to significant skin absorption, especially during activities involving sweat and open pores.
Why It Matters: The revelation of toxic chemicals in smart watch bands comes at a time when the global wrist-worn device market is experiencing significant growth. <a href="https://www.benzinga.com/24/12/42570544/apple-watch-is-getting-a-run-for-its-money-as-chinese-tech-giants-led-by-huawei-lead-20-growth-in-global-wrist-worn-device-market">Chinese tech giants </a>are challenging the dominance of established players like&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). The global market saw shipments reach 139 million units in the first three quarters of 2024, with China leading the charge.
Additionally,&nbsp;Samsung Electronics Co Ltd&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) is intensifying its <a href="https://www.benzinga.com/news/24/07/39716525/samsung-takes-on-apple-with-new-galaxy-ring-and-watch-ultra">competition with Apple</a> by launching new wearables, including the Galaxy Ring and Watch Ultra. As the market expands, the potential health risks associated with PFAS in smart watch bands could become a significant concern for consumers and manufacturers alike.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42664762/after-investing-nearly-14-billion-in-openai-microsoft-reportedly-moves-to-reduce-its-dependence-on-chatgpt-parent?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Microsoft Invested Nearly $14 Billion In OpenAI But Now Its Reducing Its Dependence On The ChatGPT-Parent</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image: Shutterstock/ Usoltsev Kirill

AAPL

SSNLF

Your Smart Watch Band Might Contain Toxic, Cancer-Linked 'Forever Chemicals,' Study Reveals

GameStop shares are trading higher. Retail trader 'Roaring Kitty' posted a picture of a Christmas present on X.

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) could ride the artificial intelligence boom, with its crown jewel iPhone expected to witness a "multi-year" upgrade cycle, according to an analyst.
What Happened: Tech bull and Wedbush analyst Dan Ives believes that Apple's iPhone sales could witness a boost thanks to AI.
"Raising price target on Apple to $325 as a golden era of growth for Cupertino is now on the horizon into 2025," said Ives in a post on X.
Apple stock closed at $258.20 on Tuesday, up 1.2% for the day. Year-to-date, Apple shares have gained 39%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. Ives&#8217; $325 price target implies a 26% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AAPL/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/26081608/Screenshot-2024-12-26-at-6.46.00%E2%80%AFPM-1024x385.png" alt="" class="wp-image-707606" /></a></figure>
While Apple has been a little late to the AI game, having been beaten by its rivals Alphabet Inc.'s Google, and Samsung Electronics Co. Ltd., <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">the Cupertino-based company unveiled</a> the Apple Intelligence suite of AI features with the iPhone 16 series in September.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Ives expects Apple to benefit significantly from the consumer AI revolution, positioning it for substantial growth through 2025.
"We believe Apple is heading into a multi-year AI driven iPhone upgrade cycle still being underestimated by the Street."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Raising price target on Apple to $325 as a golden era of growth for Cupertino is now on the horizon into 2025. We believe Apple is heading into a multi-year AI driven iPhone upgrade cycle still being underestimated by the Street. The consumer AI Revolution goes thru &#x1f34e; &#x1f525;&#x1f402;&#x1f34e;&#x1f34f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1872250576370913362?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/tech/24/12/42641667/is-this-nancy-pelosis-stock-pick-set-to-overtake-nvidia-ai-chip-race-to-heat-up-by-2025-as-meta-and-microsoft-look-beyond-jensen-huangs-chip-maker-says-expert?itm_source=parsely-api">Is This Nancy Pelosi&#8217;s Stock Pick Set To Overtake Nvidia?</a>
Why It Matters: The recent price target hike aligns with <a href="https://www.benzinga.com/markets/equities/24/12/42664887/apples-near-term-success-will-be-driven-by-strong-holiday-season-iphone-16-says-dan-ives-analyst-sees-stock-hitting-300-cupertino-hitting-4-trillion-marketcap">Ives' previous predictions</a>, which foresees Apple reaching a $4 trillion market capitalization by early 2025. This projection is driven by strong iPhone sales and AI innovations.
Recent supply chain checks in Asia indicate robust iPhone 16 upgrade trends, particularly during the holiday season. Ives believes that the success of the iPhone 16 will serve as a launchpad for a renaissance of growth in Cupertino over the next 12 to 18 months.
Furthermore, <a href="https://www.benzinga.com/markets/equities/24/12/42477035/dan-ives-predicts-apple-to-ship-record-240-million-iphones-in-2025-sparking-multi-year-supercycle-as-ai-integration-drives-growth">Ives predicts</a> that Apple will ship a record 240 million iPhones in 2025, setting a new annual record as AI features in the iPhone 16 spark a &#8220;multi-year supercycle.&#8221; This projection underscores the significance of AI integration in consumer devices, with Apple Inc. leading the charge.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42642020/steve-ballmers-bold-investment-strategy-80-of-his-portfolio-is-in-microsoft-stock-heres-why-his-keep-it-simple-approach-is-winning-big?itm_source=parsely-api">Steve Ballmer&#8217;s Winning Investment Strategy: Billionaire Says &#8216;Keep It Simple&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Pexels

Analyst Color

Price Target

Tech

Tech Bull Predicts 26% Upside For Apple Stock, Sees 'Golden Era Of Growth' For Cupertino Due To Multi-Year AI-Driven iPhone Upgrade Cycle

CHEK

Check-Cap Approves $6M Loan To Nobul AI From Segregated Account At 5% Annual Interest To Support Acquisition Targets And Growth Initiatives, With Repayment Linked To Business Combination Outcome

COEP

Coeptis Therapeutics Acquires NexGenAI Affiliates Network Platform And Launches Coeptis Technologies To Drive AI Innovation In Biotech And Technology, Expanding Growth Potential With Advanced Marketing And Automation Tools

TScan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42681377/tscan-therapeutics-announces-30-million-registered-direct-offering-at-a-37-premium" rel="noreferrer noopener">premarket session on Thursday.</a>
The firm announced a significant financing deal, entering into a securities purchase agreement with Lynx1 Capital Management LP and an investment fund advised by Lynx1.
Under the agreement, TScan will sell approximately $30 million in pre-funded warrants, which are exercisable for up to 7.50 million shares of its voting common stock.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TCRX stock has lost over 51% in the past year.&nbsp;
Each warrant will be priced at $4.00, with an exercise price of $0.0001 per share.
This deal represents a 37% premium over TScan&#8217;s last closing price and a 34% premium compared to its 10-day volume-weighted average closing price. The financing is expected to close by December 27, 2024, pending customary closing conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42681352/us-futures-tumble-after-christmas-break-but-analysts-still-expect-a-santa-claus-rally" rel="noreferrer noopener">US Stocks Likely To Open In Red After Christmas Break But Analysts Still Expect A Santa Rally Into The New Year</a>
Gavin MacBeath, Ph.D., CEO of TScan Therapeutics, expressed appreciation for Lynx1&#8217;s continued support, highlighting the investment as a testament to their commitment to TScan&#8217;s mission of delivering life-changing TCR-T cell therapies for cancer patients.
Jason A. Amello, CFO of TScan, added that the additional $30 million in gross proceeds will extend the company&#8217;s cash runway, now expected to fund operations into the first quarter of 2027, up from the previous expectation of the fourth quarter of 2026.
This funding comes after TScan filed a registration statement with the SEC in November 2022, which was declared effective in May 2023.
Price Action: TCRX shares are trading higher by 16.8% to $3.40 premarket at last check Thursday.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678014/top-7-blue-chip-stocks-with-the-best-return-potential-going-into-2025" rel="noreferrer noopener">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq's Surge</a>
Photo via Shutterstock.

Health Care

Offerings

TCRX

Why Is TScan Therapeutics Stock Gaining Today?

WISA

WiSA Technologies Signs Definitive Agreement To Acquire CompuSystems, Anticipating $13M-$15M Revenue And $3M-$4M EBITDA In 2025; Acquisition Enhances Event Data Monetization And Activates ADIO Technology For 1.4M Attendees; Conference Call Scheduled For December 30, 2024, At 11 AM ET; Financial Terms Not Disclosed

Despite bearish price action, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has seen a significant uptick in whale activity, fueling speculation of <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">an impending bullish phase</a> among traders.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.3167&nbsp;</td>
<td>$46.7 Billion</td>
<td>-4.2%&nbsp;</td>
<td>-12.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002171</td>
<td>$12.8 Billion</td>
<td>-5.4%</td>
<td>-9.7%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001738  </td>
<td>$7.3 billion</td>
<td>-6.9%&nbsp;</td>
<td>-9.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Javon Marks <a href="https://x.com/JavonTM1/status/1871995033685311804">highlighted</a> historical patterns, suggesting Dogecoin could rise beyond the 1.618 Fibonacci Extension level, as it has in previous cycles. If this scenario repeats, DOGE could surge by 570%, reaching $2.28 or higher.
Crowtrades remains confident, declaring &#8220;$1 is a promise.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Dogecoin to $1 ain&#39;t a meme, it&#39;s a promise.<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> <a href="https://t.co/gpgMnwQEwZ">https://t.co/gpgMnwQEwZ</a> <a href="https://t.co/vy2JAwG8Bu">pic.twitter.com/vy2JAwG8Bu</a>
&mdash; CROW (@TheCrowtrades) <a href="https://twitter.com/TheCrowtrades/status/1871824957715681664?ref_src=twsrc%5Etfw">December 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Tardigrade, another trader, <a href="https://x.com/TATrader_Alan/status/1871823205708738568">observed</a> consolidation patterns similar to those preceding Dogecoin's January 2021 pump. He predicts that January 2025 could mark another explosive breakout.
Statistics: Coinglass data shows Dogecoin's short liquidations of $845,000 are the lowest since Oct. 25.
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1871651560540762452">noted</a> in a post on X on Wednesday that whales purchased 270 million DOGE over the past four days. This raises curiosity among traders if significant whale movement implies an upcoming bull run for the meme coin.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42645811/dogecoin-shiba-inu-could-underperform-stronger-cryptos-trader-warns-heres-why">Dogecoin, Shiba Inu Could Underperform Stronger Cryptos, Trader Warns: Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Dogecoin Price Down 4%: What Is Going On?

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.69</td>
<td align="right">0.05</td>
<td align="right">0.05</td>
<td>4.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">134.20</td>
<td align="right">0.04</td>
<td align="right">0.02</td>
<td>295</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">97.88</td>
<td align="right">-1.29</td>
<td align="right">-1.31</td>
<td>526</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">79.09</td>
<td align="right">-0.35</td>
<td align="right">-0.45</td>
<td>2.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.18</td>
<td align="right">-0.30</td>
<td align="right">-0.40</td>
<td>1.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">138.83</td>
<td align="right">-0.49</td>
<td align="right">-0.36</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.68</td>
<td align="right">-0.85</td>
<td align="right">-0.36</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.86</td>
<td align="right">-0.13</td>
<td align="right">-0.27</td>
<td>16.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">234.36</td>
<td align="right">-0.11</td>
<td align="right">-0.05</td>
<td>180</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 26, 2024

Toyota shares are trading higher following a recent report suggesting the company is seeking a 20% return-on-equity target. The stock may also be reacting to the Nissan-Honda merger agreement.

ASMB

Assembly Biosciences Reports Interim Phase 1b Results From Trial Evaluating ABI-4334 In Chronic Hepatitis B; Says ABI-4334 Was Well Tolerated And Showed Mean Reduction Of 2.9 log IU/mL In Plasma HBV DNA Over 28 Days Of Treatment

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), with a price target o...

IO Biotech Receives Buy Rating Amid Promising Phase 2 Results and Future Potential in Cancer Treatments

IO Biotech (IOBT) announced data from the NSCLC cohort in the company's Phase 2 basket trial of IO102-IO103, the company's lead investigational can...

IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA

Morgan Stanley analyst Michael Ulz maintained a Buy rating on IO Biotech (IOBT – Research Report) yesterday and set a price target of $6.00. Michae...

Promising Potential of IO Biotech: Buy Rating Backed by Strong Phase 2 Data and Strategic Growth Plans

IO Biotech GAAP EPS of -$0.36 misses by $0.09

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of $12.00. Emily...

Positive Outlook for IO Biotech Amid Promising Clinical Developments in Melanoma and Head & Neck Cancer Trials

TD Cowen analyst Yaron Werber has maintained their bullish stance on IOBT stock, giving a Buy rating yesterday. Yaron Werber has given his Buy rati...

Promising Clinical Progress and Financial Stability Drive Buy Rating for IO Biotech

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on IO Biotech (IOBT – Research Report). The associated price target remains ...

Promising Prospects for IO Biotech Driven by Phase 3 Melanoma Study and Strong Financial Position

IO Biotech (IOBT) entered into a loan facility of up to EUR 57.5M from the European Investment Bank. The debt facility includes three committed tra...

IO Biotech secures up to EUR 57.5M in debt financing

The latest announcement is out from IO Biotech ( ($IOBT) ). IO Biotech has secured a loan facility of up to €57.5 million from the European Investm...

IO Biotech Secures €57.5 Million EIB Loan Facility

IO Biotech announces up to €57.5M debt financing from the European Investment Bank

Press Releases

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Financing

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Comments

IO Biotech

IO Biotech (IOBT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga